A combined α7 nicotinic acetylcholine receptor agonist and monoamine reuptake inhibitor, NS9775, represents a novel profile with potential benefits in emotional and cognitive disturbances

Jesper T Andreasen; John P Redrobe; Elsebet Ø Nielsen; Jeppe K Christensen; Gunnar M Olsen; Dan Peters

doi:10.1016/j.neuropharm.2013.04.060

A combined α7 nicotinic acetylcholine receptor agonist and monoamine reuptake inhibitor, NS9775, represents a novel profile with potential benefits in emotional and cognitive disturbances

Jesper T Andreasen, John P Redrobe, Elsebet Ø Nielsen, Jeppe K Christensen, Gunnar M Olsen, Dan Peters

10 Citations (Scopus)

Abstract

As affective and cognitive disturbances frequently co-occur in psychiatric disorders, research into opportunities to simultaneously target both entities is warranted. These disorders are typically treated with monoamine reuptake inhibitors (MRIs), whereas ongoing research suggests that symptoms also improve by nicotinic acetylcholine receptor (nAChR) activation. Preclinical studies have corroborated this and also demonstrated a synergistic antidepressant-like action when nAChR agonists and MRIs are combined. Here, we present the in vitro and in vivo profile of NS9775, a combined full α7 nAChR agonist and triple MRI. NS9775 potently inhibited [³H]α-bungarotoxin binding in vitro (Ki: 1.8 nM), and ex vivo (ED50: 3.6 mg/kg), showing negligible activity at α4β2-(Ki: 1720 nM) or a1-containing nAChRs (Ki: 12,200 nM). In α7-expressing oocytes, NS9775 displayed an EC₅₀ value of 280 nM, with a maximal response of 77% relative to a saturating acetylcholine concentration. Furthermore, NS9775 inhibited cortical [³H]5-HT, [³H]NA and [³H]DA uptake equipotently (14-43 nM), and inhibited striatal [³H]WIN35,428 binding (ED50: 9.1 mg/kg). Behaviourally in mice, NS9775 (0.3-3.0 mg/kg) reversed scopolamine-induced deficits in a modified Y-maze and MK-801-induced learning deficits in 5-trial inhibitory avoidance. Swim distance in the forced swim test was increased by 30 mg/kg NS9775, and 10 and 30 mg/kg NS9775 reduced digging behaviour in the marble burying paradigm and increased the number of punished crossings in the four plate test. This pro-cognitive, antidepressant-like and anxiolytic-like effect of NS9775 suggests that combining α7 nAChR agonism and triple monoamine reuptake inhibition could be a step in the evolution of pharmacological treatments of affective and/or cognitive disturbances.

Original language	English
Journal	Neuropharmacology
Volume	73
Pages (from-to)	183-91
Number of pages	9
ISSN	0028-3908
DOIs	https://doi.org/10.1016/j.neuropharm.2013.04.060
Publication status	Published - Oct 2013

Access to Document

10.1016/j.neuropharm.2013.04.060

Cite this

Andreasen, J. T., Redrobe, J. P., Nielsen, E. Ø., Christensen, J. K., Olsen, G. M., & Peters, D. (2013). A combined α7 nicotinic acetylcholine receptor agonist and monoamine reuptake inhibitor, NS9775, represents a novel profile with potential benefits in emotional and cognitive disturbances. Neuropharmacology, 73, 183-91. https://doi.org/10.1016/j.neuropharm.2013.04.060

A combined α7 nicotinic acetylcholine receptor agonist and monoamine reuptake inhibitor, NS9775, represents a novel profile with potential benefits in emotional and cognitive disturbances. / Andreasen, Jesper T; Redrobe, John P; Nielsen, Elsebet Ø et al.
In: Neuropharmacology, Vol. 73, 10.2013, p. 183-91.

Research output: Contribution to journal › Journal article › Research › peer-review

@article{e1231cca691a461ba6aaf1dc021ee9c8,

title = "A combined α7 nicotinic acetylcholine receptor agonist and monoamine reuptake inhibitor, NS9775, represents a novel profile with potential benefits in emotional and cognitive disturbances",

abstract = "As affective and cognitive disturbances frequently co-occur in psychiatric disorders, research into opportunities to simultaneously target both entities is warranted. These disorders are typically treated with monoamine reuptake inhibitors (MRIs), whereas ongoing research suggests that symptoms also improve by nicotinic acetylcholine receptor (nAChR) activation. Preclinical studies have corroborated this and also demonstrated a synergistic antidepressant-like action when nAChR agonists and MRIs are combined. Here, we present the in vitro and in vivo profile of NS9775, a combined full α7 nAChR agonist and triple MRI. NS9775 potently inhibited [3H]α-bungarotoxin binding in vitro (Ki: 1.8 nM), and ex vivo (ED50: 3.6 mg/kg), showing negligible activity at α4β2-(Ki: 1720 nM) or a1-containing nAChRs (Ki: 12,200 nM). In α7-expressing oocytes, NS9775 displayed an EC50 value of 280 nM, with a maximal response of 77% relative to a saturating acetylcholine concentration. Furthermore, NS9775 inhibited cortical [3H]5-HT, [3H]NA and [3H]DA uptake equipotently (14-43 nM), and inhibited striatal [3H]WIN35,428 binding (ED50: 9.1 mg/kg). Behaviourally in mice, NS9775 (0.3-3.0 mg/kg) reversed scopolamine-induced deficits in a modified Y-maze and MK-801-induced learning deficits in 5-trial inhibitory avoidance. Swim distance in the forced swim test was increased by 30 mg/kg NS9775, and 10 and 30 mg/kg NS9775 reduced digging behaviour in the marble burying paradigm and increased the number of punished crossings in the four plate test. This pro-cognitive, antidepressant-like and anxiolytic-like effect of NS9775 suggests that combining α7 nAChR agonism and triple monoamine reuptake inhibition could be a step in the evolution of pharmacological treatments of affective and/or cognitive disturbances.",

keywords = "Affective Symptoms, Animals, Avoidance Learning, Behavior, Animal, Brain, Bungarotoxins, Cognition Disorders, Drug Evaluation, Preclinical, Female, Male, Maze Learning, Mice, Naphthalenes, Neurotransmitter Uptake Inhibitors, Nicotinic Agonists, Punishment, Radioligand Assay, Tritium",

author = "Andreasen, {Jesper T} and Redrobe, {John P} and Nielsen, {Elsebet {\O}} and Christensen, {Jeppe K} and Olsen, {Gunnar M} and Dan Peters",

year = "2013",

month = oct,

doi = "10.1016/j.neuropharm.2013.04.060",

language = "English",

volume = "73",

pages = "183--91",

journal = "Neuropharmacology",

issn = "0028-3908",

publisher = "Pergamon Press",

}

TY - JOUR

T1 - A combined α7 nicotinic acetylcholine receptor agonist and monoamine reuptake inhibitor, NS9775, represents a novel profile with potential benefits in emotional and cognitive disturbances

AU - Andreasen, Jesper T

AU - Redrobe, John P

AU - Nielsen, Elsebet Ø

AU - Christensen, Jeppe K

AU - Olsen, Gunnar M

AU - Peters, Dan

PY - 2013/10

Y1 - 2013/10

N2 - As affective and cognitive disturbances frequently co-occur in psychiatric disorders, research into opportunities to simultaneously target both entities is warranted. These disorders are typically treated with monoamine reuptake inhibitors (MRIs), whereas ongoing research suggests that symptoms also improve by nicotinic acetylcholine receptor (nAChR) activation. Preclinical studies have corroborated this and also demonstrated a synergistic antidepressant-like action when nAChR agonists and MRIs are combined. Here, we present the in vitro and in vivo profile of NS9775, a combined full α7 nAChR agonist and triple MRI. NS9775 potently inhibited [3H]α-bungarotoxin binding in vitro (Ki: 1.8 nM), and ex vivo (ED50: 3.6 mg/kg), showing negligible activity at α4β2-(Ki: 1720 nM) or a1-containing nAChRs (Ki: 12,200 nM). In α7-expressing oocytes, NS9775 displayed an EC50 value of 280 nM, with a maximal response of 77% relative to a saturating acetylcholine concentration. Furthermore, NS9775 inhibited cortical [3H]5-HT, [3H]NA and [3H]DA uptake equipotently (14-43 nM), and inhibited striatal [3H]WIN35,428 binding (ED50: 9.1 mg/kg). Behaviourally in mice, NS9775 (0.3-3.0 mg/kg) reversed scopolamine-induced deficits in a modified Y-maze and MK-801-induced learning deficits in 5-trial inhibitory avoidance. Swim distance in the forced swim test was increased by 30 mg/kg NS9775, and 10 and 30 mg/kg NS9775 reduced digging behaviour in the marble burying paradigm and increased the number of punished crossings in the four plate test. This pro-cognitive, antidepressant-like and anxiolytic-like effect of NS9775 suggests that combining α7 nAChR agonism and triple monoamine reuptake inhibition could be a step in the evolution of pharmacological treatments of affective and/or cognitive disturbances.

AB - As affective and cognitive disturbances frequently co-occur in psychiatric disorders, research into opportunities to simultaneously target both entities is warranted. These disorders are typically treated with monoamine reuptake inhibitors (MRIs), whereas ongoing research suggests that symptoms also improve by nicotinic acetylcholine receptor (nAChR) activation. Preclinical studies have corroborated this and also demonstrated a synergistic antidepressant-like action when nAChR agonists and MRIs are combined. Here, we present the in vitro and in vivo profile of NS9775, a combined full α7 nAChR agonist and triple MRI. NS9775 potently inhibited [3H]α-bungarotoxin binding in vitro (Ki: 1.8 nM), and ex vivo (ED50: 3.6 mg/kg), showing negligible activity at α4β2-(Ki: 1720 nM) or a1-containing nAChRs (Ki: 12,200 nM). In α7-expressing oocytes, NS9775 displayed an EC50 value of 280 nM, with a maximal response of 77% relative to a saturating acetylcholine concentration. Furthermore, NS9775 inhibited cortical [3H]5-HT, [3H]NA and [3H]DA uptake equipotently (14-43 nM), and inhibited striatal [3H]WIN35,428 binding (ED50: 9.1 mg/kg). Behaviourally in mice, NS9775 (0.3-3.0 mg/kg) reversed scopolamine-induced deficits in a modified Y-maze and MK-801-induced learning deficits in 5-trial inhibitory avoidance. Swim distance in the forced swim test was increased by 30 mg/kg NS9775, and 10 and 30 mg/kg NS9775 reduced digging behaviour in the marble burying paradigm and increased the number of punished crossings in the four plate test. This pro-cognitive, antidepressant-like and anxiolytic-like effect of NS9775 suggests that combining α7 nAChR agonism and triple monoamine reuptake inhibition could be a step in the evolution of pharmacological treatments of affective and/or cognitive disturbances.

KW - Affective Symptoms

KW - Animals

KW - Avoidance Learning

KW - Behavior, Animal

KW - Brain

KW - Bungarotoxins

KW - Cognition Disorders

KW - Drug Evaluation, Preclinical

KW - Female

KW - Male

KW - Maze Learning

KW - Mice

KW - Naphthalenes

KW - Neurotransmitter Uptake Inhibitors

KW - Nicotinic Agonists

KW - Punishment

KW - Radioligand Assay

KW - Tritium

U2 - 10.1016/j.neuropharm.2013.04.060

DO - 10.1016/j.neuropharm.2013.04.060

M3 - Journal article

C2 - 23748055

SN - 0028-3908

VL - 73

SP - 183

EP - 191

JO - Neuropharmacology

JF - Neuropharmacology

ER -

A combined α7 nicotinic acetylcholine receptor agonist and monoamine reuptake inhibitor, NS9775, represents a novel profile with potential benefits in emotional and cognitive disturbances

Abstract

Access to Document

Fingerprint

Cite this